Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at William Blair boosted their Q2 2025 earnings estimates for shares of Zevra Therapeutics in a research report issued on Monday, July 14th. William Blair analyst S. Corwin now anticipates that the company will earn $2.26 per share for the quarter, up from their previous forecast of $0.09. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' FY2025 earnings at $2.08 EPS and FY2026 earnings at $0.13 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the business posted ($0.40) EPS.

A number of other brokerages have also recently issued reports on ZVRA. Wall Street Zen raised shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. HC Wainwright began coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald lifted their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zevra Therapeutics has an average rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA traded up $0.37 during trading hours on Wednesday, hitting $12.69. 1,009,894 shares of the stock were exchanged, compared to its average volume of 731,614. The company's fifty day simple moving average is $9.36 and its two-hundred day simple moving average is $8.29. The company has a market cap of $693.62 million, a PE ratio of -6.66 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. Zevra Therapeutics has a 1-year low of $5.45 and a 1-year high of $13.16.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC raised its stake in shares of Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after acquiring an additional 8,020 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after acquiring an additional 4,384 shares during the last quarter. Strs Ohio bought a new position in shares of Zevra Therapeutics during the first quarter valued at $125,000. Finally, ProShare Advisors LLC bought a new position in shares of Zevra Therapeutics during the fourth quarter valued at $145,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.